logo
Plus   Neg
Share
Email

Sanofi :Sutimlimab Meets Primary Endpoint In Phase 3 Trial For Patients With CAD

Sanofi (SNYNF,SNY) said that Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease or CAD.

CAD is a severe and chronic rare blood disorder in which the immune system mistakenly attacks a person's own healthy red blood cells.

There are currently no approved therapies for CAD. People with CAD suffer from chronic hemolytic anemia and debilitating fatigue. Sutimlimab is the first investigational complement inhibitor for the treatment of CAD to present Phase 3 data.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. (INTC), the world's biggest chipmaker, Thursday said its profit and revenues for the fourth quarter trumped Wall Street estimates. The company's shares gained nearly 7 percent driven by strong outlook for the first quarter and full year 2020. Santa Clara, California-based Intel reported... ABH Pharma, Inc. and Stocknutra.com Inc. have recalled all of its dietary supplement products pursuant to a consent decree entered by the U.S. District Court for the Eastern District of New York. The companies have recalled all dietary supplement products manufactured and sold between January 2013... New York-based grocery chain Fairway Market has filed for Chapter 11 bankruptcy protection, but said its stores will remain open across the Tri-State area during the court process and it does not expect any service interruptions. This is the second time the company has filed for bankruptcy. The company earlier filed for Chapter 11 bankruptcy protection in 2016.
Follow RTT
>